Results 211 to 220 of about 37,897 (253)

Esketamine Nasal Spray versus Quetiapine for Treatment-Resistant Depression.

New England Journal of Medicine, 2023
BACKGROUND In treatment-resistant depression, commonly defined as a lack of response to two or more consecutive treatments during the current depressive episode, the percentage of patients with remission is low and the percentage with relapse is high ...
A. Reif, I. Bitter, J. Buyze, Kerstin Cebulla, R. Frey, Dong-Jing Fu, T. Ito, Y. Kambarov, P. Llorca, A. Oliveira-Maia, T. Messer, S. Mulhern-Haughey, B. Rive, Christian von Holt, A. Young, Y. Godinov   +15 more
semanticscholar   +1 more source

Quetiapine Abuse Fourteen Years Later: Where Are We Now? A Systematic Review

Substance Use & Misuse, 2020
Background: Quetiapine, an atypical antipsychotic endowed with weak dopamine antagonist, potent 5-HT2A-blocking, partial 5-HT1A-agonist, anti-H1 histamine, adrenolytic, and sigma1 receptor agonist activities, since an original 2004 report is increasingly
Alessandro Vento, G. Kotzalidis, M. Cacciotti, G. Papanti, L. Orsolini, C. Rapinesi, Valeria Savoja, Giuseppa Calabrò, A. Del Casale, D. Piacentino, M. Caloro, P. Girardi, F. Schifano   +12 more
semanticscholar   +1 more source

The efficacy and tolerability of once-daily extended release quetiapine fumarate in hospitalized patients with acute schizophrenia: a 6-week randomized, double-blind, placebo-controlled study.

Psychopharmacology bulletin
OBJECTIVES This study aimed to demonstrate efficacy of once-daily extended release quetiapine fumarate (quetiapine XR) versus placebo in patients with acute schizophrenia.
J. Lindenmayer, David Brown, S. Liu, M. Brecher, D. Meulien   +4 more
semanticscholar   +1 more source